Alumis (ALMS) Faces Pressure After Clinical Results Soumya Eswaran Thu, November 12, 2026 at 12:27 PM EST 2 min read ALMS -4.38% ^GSPC +0.09% ^IXIC -0.00% ^RUT -0.83% Trade Alumis on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Voya Investment Management, an investment management company, released its third-quarter 2026 investor letter for its "Voya MI Dynamic Small Cap Fund." The letter can be downloaded here. U.S. equities posted modest gains in the third quarter, led particularly by large-cap technology and energy companies. The S&P 500 rose 2.30%, while the Nasdaq gained 2.47%, supported by economic growth, strong corporate earnings, and enthusiasm for artificial intelligence (AI). Despite persistent inflation pressures and a Federal Reserve rate hike, stable labor conditions and earnings-growth forecasts helped sustain investor confidence. Sector performance varied during the quarter, with energy, information technology, and healthcare outperforming, while utilities and real estate lagged. The Fund outperformed its benchmark, the Russell 2000, driven by favorable stock selection in industrials, information technology, and financials sectors. Looking ahead, the firm believes strong growth and AI-related investment continue to support U.S. equities, although inflation and interest-rate risks remain. Key factors affecting future equity performance include inflation, interest rates, earnings growth, and growing AI adoption. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q3 2026 investor letter, Voya MI Dynamic Small Cap Fund noted that its overweight position in Alumis Inc. (NASDAQ:ALMS) detracted from performance. Alumis Inc. (NASDAQ:ALMS) is a clinical stage biopharmaceutical company focusing on developing medicines for autoimmune disorders. On November 11, 2026, Alumis Inc. (NASDAQ:ALMS) closed at $6.62 per share with a market capitalization of $883.74 million. Shares of Alumis Inc. (NASDAQ:ALMS) rose 4.91% over the past month, extending its 52-week gain to 25.38%.
Voya MI Dynamic Small Cap Fund stated the following regarding Alumis Inc. (NASDAQ:ALMS) in its Q3 2026 investor letter:
"The overweight position in Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company, detracted from performance. Shares declined following disappointing clinical trial results. The overweight was primarily driven by risk management reasons."
FREE REPORT: What are billionaires buying right now? While we acknowledge the potential of Alumis Inc. (NASDAQ:ALMS) as an investment, you should take a look at these billionaire-backed stocks before making your next move. Insider Monkey just released an exclusive look into the hidden portfolios of the world's top fund managers. Get instant, free access to the "7 Stocks Warren Buffett & Billionaires Are Quietly Hoarding" report and join 2.5 million monthly readers leveraging elite hedge fund data to build wealth. Get it NOW!
In another article on Alumis Inc. (NASDAQ:ALMS), we noted that it missed primary endpoints in its Phase 2b lupus trial for envudeucitinib, but it will consult regulators to discuss a Phase 3 trial. In addition, please check out our hedge fund investor letters Q3 2026 page for more investor letters from hedge funds and other leading investors.
This article is originally published at Insider Monkey.
